Horizon Global (HZN) Forms $8.06 Double Bottom; ICU Medical, Inc. (ICUI) Had 3 Bullish Analysts

Horizon Global Corporation (NYSE:HZN) Logo

Among 5 analysts covering ICU Medical (NASDAQ:ICUI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ICU Medical had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Monday, August 17. On Tuesday, August 11 the stock rating was maintained by Piper Jaffray with “Overweight”. The company was maintained on Friday, August 11 by Gabelli. The rating was maintained by Roth Capital with “Buy” on Tuesday, August 11. TH Capital maintained it with “Buy” rating and $130 target in Friday, November 6 report. The stock has “Buy” rating by Roth Capital on Friday, November 6. On Friday, March 11 the stock rating was initiated by Gabelli with “Buy”. TH Capital maintained the shares of ICUI in report on Tuesday, August 11 with “Buy” rating. Roth Capital maintained the shares of ICUI in report on Wednesday, August 9 with “Hold” rating. See ICU Medical, Inc. (NASDAQ:ICUI) latest ratings:

17/10/2017 Broker: KeyBanc Capital Markets Rating: Sector Weight Initiates Coverage On

Horizon Global Corporation (HZN) formed double bottom with $7.50 target or 7.00% below today’s $8.06 share price. Horizon Global Corporation (HZN) has $201.58 million valuation. The stock decreased 3.93% or $0.33 during the last trading session, reaching $8.06. About 321,330 shares traded. Horizon Global Corporation (NYSE:HZN) has declined 36.53% since April 9, 2017 and is downtrending. It has underperformed by 48.08% the S&P500.

Among 10 analysts covering Horizon Global Corporation (NYSE:HZN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Horizon Global Corporation had 22 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Wells Fargo on Tuesday, February 21 with “Market Perform”. On Tuesday, September 5 the stock rating was downgraded by Bank of America to “Sell”. Roth Capital maintained Horizon Global Corporation (NYSE:HZN) on Friday, January 26 with “Buy” rating. The stock of Horizon Global Corporation (NYSE:HZN) earned “Hold” rating by BMO Capital Markets on Monday, January 29. The stock has “Buy” rating by BMO Capital Markets on Thursday, July 13. The rating was maintained by Barrington with “Buy” on Friday, March 9. BMO Capital Markets maintained it with “Outperform” rating and $20 target in Wednesday, August 2 report. The firm has “Buy” rating by Roth Capital given on Friday, December 15. The rating was upgraded by Bank of America to “Buy” on Wednesday, February 7. Seaport Global upgraded Horizon Global Corporation (NYSE:HZN) rating on Wednesday, March 2. Seaport Global has “Speculative Buy” rating and $13 target.

Analysts await Horizon Global Corporation (NYSE:HZN) to report earnings on May, 2. They expect $-0.04 EPS, up 76.47% or $0.13 from last year’s $-0.17 per share. After $-0.11 actual EPS reported by Horizon Global Corporation for the previous quarter, Wall Street now forecasts -63.64% EPS growth.

The stock decreased 1.28% or $3.25 during the last trading session, reaching $249.85. About 92,115 shares traded. ICU Medical, Inc. (NASDAQ:ICUI) has risen 61.26% since April 9, 2017 and is uptrending. It has outperformed by 49.71% the S&P500.

Since October 9, 2017, it had 0 buys, and 4 sales for $32.24 million activity. LOPEZ GEORGE A had sold 33,000 shares worth $8.30 million on Monday, March 19. On Monday, October 9 the insider SAUCEDO JOSEPH R sold $1.71 million. Shares for $170,140 were sold by SWINNEY ROBERT S on Friday, January 19. $18.58 million worth of stock was sold by Jain Vivek on Thursday, October 19. Lamb Scott E sold $5.20M worth of stock or 23,624 shares.

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. The company has market cap of $5.06 billion. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patientÂ’s vein for use in hospitals and ambulatory clinics. It has a 75.94 P/E ratio. The companyÂ’s infusion therapy products include needlefree connector products, such as MicroClave and MicroClave Clear, Neutron, NanoClave, Clave, and SwabCap; custom infusion sets; and Tego needlefree hemodialysis connectors.

ICU Medical, Inc. (NASDAQ:ICUI) Institutional Positions Chart